Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VOLITIONRX LTDVNRX · Entity 8241 | Group Chief Marketing Officer | February 26, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VOLITIONRX LTD
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 324,072 |
Reported balance
After 2026-02-26 transaction · row 1
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 142,000 · Balance 324,072 F1: On February 26, 2026, the reporting person was awarded 142,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been both earned and vested as of the vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 29,406 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 29,406 |
Filing footnotes · ownership attribution and instrument terms
F1: On February 26, 2026, the reporting person was awarded 142,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been both earned and vested as of the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed Feb 27, 2026 21:31 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 142,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-26-001102 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,072 F1 · shares: On February 26, 2026, the reporting person was awarded 142,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been both earned and vested as of the vesting date. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 21:07 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 33,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-26-000367 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,072 F1 · shares: On March 17, 2025, the reporting person was awarded 113,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 33,900 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 11,300 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 79,100 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively. Read SEC document |
| October 04, 2025 Filed Oct 7, 2025 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 6,110 | $0.65 | $3,959.28 |
DisclosureSEC source: 0001477932-25-007406 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,172 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 13,000 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| September 28, 2025 Filed Sep 30, 2025 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 5,604 | $0.61 | $3,390.42 |
DisclosureSEC source: 0001477932-25-007230 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,282 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 11,925 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 27,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-006102 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,886 F1 · shares: On August 15, 2025, the reporting person was awarded 27,400 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in six approximately equal monthly installments commencing on September 1, 2025. Once earned, they will remain subject to additional time-based vesting in two equal installments of 13,700 units on each of November 1, 2025 and February 1, 2026, respectively, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 8,620 | $0.64 | $5,516.80 |
DisclosureSEC source: 0001477932-25-005472 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,486 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 18,341 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 17:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 6,177 | $0.77 | $4,743.32 |
DisclosureSEC source: 0001477932-25-004914 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,106 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 13,143 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 18,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-004366 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,283 F1 · shares: On June 1, 2025, the reporting person was awarded 18,341 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 6,114 units, 6,114 units, and 6,113 units on each of June 1, 2025, July 1, 2025 and August 1, 2025, respectively, are also subject to further time-based vesting in a single installment on August 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 14,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-001463 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,942 F1 · shares: On March 1, 2025, the reporting person was awarded 14,233 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 4,745 units, 4,744 units, and 4,744 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $3.25 | Not disclosed |
DisclosureSEC source: 0001477932-25-000609 · form4.xml · derivative · entry 2 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-02-11 F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $3.25 | Not disclosed |
DisclosureSEC source: 0001477932-25-000609 · form4.xml · derivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2025-02-11 F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 13,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-007803 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,709 F1 · shares: On December 1, 2024, the reporting person was awarded 13,143 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 4,381 units on each of December 1, 2024, January 1, 2025 and February 1, 2025, respectively, are also subject to further time-based vesting in a single installment on July 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 6,110 | $0.88 | $5,395.13 |
DisclosureSEC source: 0001477932-24-006285 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,566 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 13,000 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| September 28, 2024 Filed Oct 1, 2024 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 5,604 | $0.58 | $3,239.11 |
DisclosureSEC source: 0001477932-24-006097 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,676 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 11,925 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 20:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 13,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-005499 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,280 F1 · shares: On September 1, 2024, the reporting person was awarded 13,731 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 4,577 units on each of September 1, 2024, October 1, 2024 and November 1, 2024, respectively, are also subject to further time-based vesting in a single installment on June 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 13,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-005031 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,549 F1 · shares: On Sept 28, 2023, the reporting person was awarded 53,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to Dec 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 13,250 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 4,416 units, 4,417 units, and 4,417 units on each of Sept 28, 2024, 2025 and 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in Jan 2024, the rights with respect to 22,525 RSUs subject to the award previously vested and remain subject to time-based vesting. The rights with respect to the remaining 17,225 RSUs did not vest and were cancelled on August 15, 2024. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 11,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-003491 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,299 F1 · shares: On June 1, 2024, the reporting person was awarded 11,685 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 3,895 units on each of June 1, 2024, July 1, 2024 and August 1, 2024, respectively, are also subject to further time-based vesting in a single installment on May 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 22,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-000403 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,614 F1 · shares: On September 28, 2023, the reporting person was awarded 53,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 22,525 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 7,509 units, 7,508 units, and 7,508 units on each of September 28, 2024, September 28, 2025 and September 28, 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Tax withholdingCommon Stock | 5,819 | $1.30 | $7,564.70 |
DisclosureSEC source: 0001477932-23-005791 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,089 F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 12,062 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:03 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 17,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005122 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,908 F1 · shares: On October 4, 2022, the reporting person was awarded 39,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 17,550 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 5,850 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in October 2022 and January 2023 respectively, the rights with respect to 6,825 RSUs and 14,625 RSUs subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 21:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 14,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000267 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,358 F1 · shares: On October 4, 2022, the reporting person was awarded 39,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 14,625 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 4,875 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in October 2022, the rights with respect to 6,825 restricted stock units subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| October 13, 2022 Filed Oct 14, 2022 20:07 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 6,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-007702 · form4.xml · nonDerivative · entry 1 Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,733 F1 · shares: On October 4, 2022, the reporting person was awarded 39,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 6,825 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 2,275 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.